Title: Mutation screening of ASMT, the last enzyme of the melatonin pathway, in a large sample of patients with Intellectual Disability
Authors: Pagan, Cecile ×
Goubran-Botros, Hany
Poirier, Karine
Dumaine, Anne
Jamain, Stephane
Moreno, Sarah
de Brouwer, Arjan
Van Esch, Hilde
Delorme, Richard
Launay, Jean-Marie
Tzschach, Andreas
Kalscheuer, Vera M
Lacombe, Didier
Briault, Sylvain
Laumonnier, Frederic
Raynaud, Martine
van Bon, Bregje W
Willemsen, Marjolein H
Leboyer, Marion
Chelly, Jamel
Bourgeron, Thomas #
Issue Date: Jan-2011
Publisher: BioMed Central
Series Title: BMC Medical Genetics vol:12 issue:1 pages:17
Article number: 10.1186/1471-2350-12-17
Abstract: ABSTRACT: BACKGROUND: Intellectual disability (ID) is frequently associated with sleep disorders. Treatment with melatonin demonstrated efficacy, suggesting that, at least in a subgroup of patients, the endogenous melatonin level may not be sufficient to adequately set the sleep-wake cycles. Mutations in ASMT gene, coding the last enzyme of the melatonin pathway, have been reported as a risk factor for autism spectrum disorders (ASD), which are often comorbid with ID. The aim of this study was to ascertain the genetic variability of ASMT in a large cohort of patients with ID and controls. METHODS: We sequenced all exons of ASMT in a sample of 361 patients with ID and 440 controls. We then measured ASMT activity in B lymphoblastoid cell lines (BLCL) of patients with ID carrying an ASMT variant and compared it to controls. RESULTS: We could identify eleven variations modifying the protein sequence of ASMT (ID only: N13H, N17K, V171M, E288D ; controls only: E61Q, D210G, K219R, P243L, C273S, R291Q; ID and controls: L298F) and two deleterious splice site mutations (IVS5+2T>C and IVS7+1G>T) only observed in patients with ID. We then ascertained ASMT activity in B lymphoblastoid cell lines from patients carrying the mutations and showed significantly lower enzyme activity in patients carrying mutations compared to controls (p=0.004). CONCLUSIONS: We could identify patients with deleterious ASMT mutations as well as decreased ASMT activity. However, this study does not support ASMT as a causative gene for ID since we observed no significant enrichment in the frequency of ASMT variants in ID compared to controls. Nevertheless, given the impact of sleep difficulties in patients with ID, melatonin supplementation might be of great benefit for a subgroup of patients with low melatonin synthesis.
ISSN: 1471-2350
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Department of Human Genetics - miscellaneous
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Pagan BMC Med Genet 2011.pdfpublisher's version pdf Published 319KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science